Cabaletta Bio Inc
CABA1.515USD
+0.075+5.21%
Market hours （ET）Quotes delayed by 15 min
76.88MMarket Cap
LossP/E TTM
More Details of Cabaletta Bio Inc Company
Cabaletta Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). CABA-201, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
Company Info
Ticker SymbolCABA
Company nameCabaletta Bio Inc
IPO dateOct 25, 2019
CEODr. Steven Nichtberger, M.D.
Number of employees161
Security typeOrdinary Share
Fiscal year-endOct 25
Address2929 Arch Street
CityPHILADELPHIA
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code19104
Phone12677593100
Websitehttps://www.cabalettabio.com/
Ticker SymbolCABA
IPO dateOct 25, 2019
CEODr. Steven Nichtberger, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Steven Nichtberger, M.D.
Dr. Steven Nichtberger, M.D.
Chief Executive Officer, President, Chairman of the Board, Co-Founder
Chief Executive Officer, President, Chairman of the Board, Co-Founder
1.35M
-30.78%
Dr. Scott C. Brun, M.D.
Dr. Scott C. Brun, M.D.
Independent Director
Independent Director
--
--
Dr. David J. Chang, M.D.
Dr. David J. Chang, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Catherine Bollard, M.D.
Dr. Catherine Bollard, M.D.
Independent Director
Independent Director
--
--
Mr. Mark J. Simon
Mr. Mark J. Simon
Independent Director
Independent Director
--
--
Ms. Shawn Cline Tomasello
Ms. Shawn Cline Tomasello
Independent Director
Independent Director
--
--
Mr. Richard Conover Henriques, Jr.
Mr. Richard Conover Henriques, Jr.
Independent Director
Independent Director
--
--
Dr. Gwendolyn Knowlton (Gwen) Binder-Scholl, Ph.D.
Dr. Gwendolyn Knowlton (Gwen) Binder-Scholl, Ph.D.
President - Science and Technology
President - Science and Technology
--
--
Dr. Arun Das, M.D.
Dr. Arun Das, M.D.
Chief Business Officer
Chief Business Officer
--
--
Mr. Anup Marda
Mr. Anup Marda
Chief Financial Officer
Chief Financial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Steven Nichtberger, M.D.
Dr. Steven Nichtberger, M.D.
Chief Executive Officer, President, Chairman of the Board, Co-Founder
Chief Executive Officer, President, Chairman of the Board, Co-Founder
1.35M
-30.78%
Dr. Scott C. Brun, M.D.
Dr. Scott C. Brun, M.D.
Independent Director
Independent Director
--
--
Dr. David J. Chang, M.D.
Dr. David J. Chang, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Catherine Bollard, M.D.
Dr. Catherine Bollard, M.D.
Independent Director
Independent Director
--
--
Mr. Mark J. Simon
Mr. Mark J. Simon
Independent Director
Independent Director
--
--
Ms. Shawn Cline Tomasello
Ms. Shawn Cline Tomasello
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Jun 24
Updated: Tue, Jun 24
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Jennison Associates LLC
6.69%
Citadel Advisors LLC
5.36%
T. Rowe Price Investment Management, Inc.
4.41%
Adage Capital Management, L.P.
4.04%
The Vanguard Group, Inc.
3.84%
Other
75.66%
Shareholders
Shareholders
Proportion
Jennison Associates LLC
6.69%
Citadel Advisors LLC
5.36%
T. Rowe Price Investment Management, Inc.
4.41%
Adage Capital Management, L.P.
4.04%
The Vanguard Group, Inc.
3.84%
Other
75.66%
Shareholder Types
Shareholders
Proportion
Investment Advisor
21.50%
Hedge Fund
13.30%
Investment Advisor/Hedge Fund
9.13%
Research Firm
2.25%
Individual Investor
1.68%
Bank and Trust
0.14%
Pension Fund
0.02%
Other
51.98%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
332
43.19M
48.02%
-20.01M
2025Q1
343
38.78M
72.92%
-24.88M
2024Q4
342
40.39M
82.63%
-20.01M
2024Q3
330
50.24M
102.85%
-12.34M
2024Q2
325
53.21M
110.27%
-11.74M
2024Q1
310
53.11M
110.79%
-5.05M
2023Q4
269
50.62M
118.36%
-623.67K
2023Q3
244
42.61M
108.50%
-4.28M
2023Q2
218
38.30M
97.94%
+637.03K
2023Q1
208
26.57M
91.08%
-5.98M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Jennison Associates LLC
2.43M
2.71%
-78.33K
-3.12%
Mar 31, 2025
Citadel Advisors LLC
4.82M
5.36%
+4.82M
+1376631.43%
Jun 12, 2025
T. Rowe Price Investment Management, Inc.
3.97M
4.41%
-103.98K
-2.55%
Mar 31, 2025
Adage Capital Management, L.P.
3.63M
4.04%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
2.84M
3.16%
-23.48K
-0.82%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.11M
3.45%
+57.80K
+1.90%
Mar 31, 2025
Bain Capital Life Sciences Investors, LLC
2.76M
3.07%
--
--
Mar 31, 2025
Schonfeld Strategic Advisors LLC
1.66M
1.85%
+1.66M
--
Mar 31, 2025
Cantor Fitzgerald, L.P
1.48M
1.65%
+1.38M
+1384.59%
Mar 31, 2025
Nichtberger (Steven)
1.35M
1.5%
-600.00K
-30.78%
Apr 28, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
iShares Morningstar Small-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Humankind US Stock ETF
0%
iShares ESG Aware MSCI USA Small-Cap ETF
0%
SPDR Portfolio MSCI Global Stock Market ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.02%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0%
iShares Morningstar Small-Cap ETF
Proportion0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Humankind US Stock ETF
Proportion0%
iShares ESG Aware MSCI USA Small-Cap ETF
Proportion0%
SPDR Portfolio MSCI Global Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
